

Erika Schirinzi (Neurological Clinic, University of Pisa)
Massimo Del Sette (Ospedale Policlinico San Martino)
Christoph Stretz (Warren Alpert Medical School of Brown University)
Narendra Kala (Alpert Medical School at Brown University)
Ashley Schomer (Brown University)
Brian Mac Grory (Duke University School of Medicine)
Mahesh Jayaraman (Warren Alpert School of Medicine at Brown University)
Shadi Yaghi (Alpert Medical School at Brown University)
Karen Furie (Rhode Island Hospital)
Luca Masotti (Internal Medicine)
Elisa Grifoni (Internal Medicine, Azienda USL Toscana Centro)
Danilo Toni (University 'La Sapienza')
Angela Risitano (University La Sapienza)
Anne Falcou (policlinico Umberto 1)
Luca Petraglia (University of Rome La Sapienza)
Enrico Maria Lotti (Ospedale Infermi Rimini)
Lucia Pavolucci (U.O. Neurologia Presidio Ospedaliero di Ravenna Azienda USL della Romagna, Italy)
Piergiorgio Lochner (Saarland University Medical Center)
Giorgio Silvestrelli (ASST Mantova)
Alfonso Ciccone (Azienda Socio Sanitaria Territoriale di Mantova)
Andrea Alberti (University of Perugia)
Michele Venti (University of Perugia)
Ilaria Leone De Magistris (University of Perugia)
Maria Giulia Mosconi (Azienda Ospedaliera - Università degli Studi di Perugia)
Michela Giustozzi (University of Perugia)
Odysseas Kargiotis (Metropolitan Hospital)
Alessandro Rocco (University of Tor Vergata)
Marina Diomedei (University Hospital Tor Vergata)
Simona Marcheselli (Ircs Humanitas Clinical and Research Ospital)
Kateryna Antonenko (Inselspital, University Hospital and University of Bern, Bern, Switzerland)
Eugenia Rota (Neurology Unit)
Tiziana Tassinari (Ospedale Santa Corona)
Valentina Saia (Santa Corona Hospital)
Francesco Palmerini (Poliambulanza)
Paolo Aridon (University of Palermo)
Valentina Arnao (University of Palermo)
Serena Monaco (Civico Hospital Palermo)
Salvatore Cottone (ARNAS Civico Di Cristina Benfratelli)
Antonio Baldi (Portogruaro Hospital)
Cataldo D'Amore (AULSS 4 - Veneto Orientale)
Walter Ageno (University of Insubria)
Samuela Pegoraro (Insubria University)
George Ntaios (University of Thessaly)
Anastasia Adamou (University of Thessaly)
Dimitrios Sagris (University of Thessaly)
Sotirios Giannopoulos (University of Ioannina School of Medicine)
Maria Kosmidou (University of Ioannina)
Evangelos Ntais (University of Ioannina)
Michele Romoli ("Maurizio Bufalini" Hospital)
Leonardo Pantoni (University of Milan, Milan)
Silvia Rosa (University of Milan)
Pierluigi Bertora (University of Milan)
Alberto Chiti (Unit of Neurology, Ospedale Apuane, Massa)
Isabella Canavero (IRCCS National Neurological Institute C. Mondino)
Carlo Emanuele Saggese (ASL Frosinone)

Maurizio Plocco (ASL Frosinone)
Elisa Giorli (Sant'Andrea Hospital)
Lina Palaodimou (National and Kapodistrian University of Athens, Attikon University Hospital)
Eleni Bakola (University of Athens)
Fabio Bandini (ASL 3 Liguria)
Antonio Gasparro (Ospedali Riuniti)
Valeria Terruso (AOOR Villa Sofia-Cervello)
Marina Mannino (Stroke Unit, Ospedale Civico)
Alessandro Pezzini (Università degli studi di Parma)
Raffaele Ornello (University of L'Aquila)
Simona Sacco (University of L'Aquila)
Nemanja Popovic (Clinic of Neurology, Clinical Center Vojvodina, University of Novi Sad)
Umberto Scoditti (Azienda Ospedaliero Universitaria di Parma)
Antonio Genovese (Ospedale Universitario Parma)
Yuriy Flomin (Universal Clinic 'Oberig')
Michelangelo Mancuso (neurological clinic)
Roberto D'agliano (University of Pisa)
Marco Baldini (University of Pisa)
Leonardo Ulivi (University of Pisa)
Nicola Giannini (Clinica Neurologica - Azienda Ospedaliero-Universitaria, Pisa)
Konstantinos Vadikolias (Dept of Neurology- Democritus University of Thrace, Alexandroupolis, Greece)
Chrysoula Liantinioti (UNIVERSITY HOSPITAL 'ATTIKON')
Maria Chondrogianni (University of Athens, School of Medicine)
Panagiotis Halvatsiotis (National and Kapodistrian University of Athens, Attikon University Hospital)
Efstathia Karagkiozi (University of Thessaly)
George Athanasakis (University of Thessaly)
Konstantinos Makaritsis (Larissa, Medical School, University of Thessaly)
alessia lanari (ospedale c. poma)
Turgut Tatlisumak (Institute of Neuroscience and Physiology)
Monica Acciarresi (University of Perugia)
Gianni Lorenzini (Cecina Hospital)
Rossana Tassi (Stroke Unit Azienda Ospedaliera Universitaria Senese)
Francesca Guideri (Stroke Unit)
Maurizio Acampa (Azienda Ospedaliera Universitaria Senese)
Giuseppe Martini (University of Siena)
Sung-Il Sohn (Dongsan Hospital, Keimyung University School of Medicine)
Nicola Mumoli (Internal Medicine Department)
Davide Cararra (USL Toscana nordovest)
Miriam Maccarrone (University of Pisa)
Franco Galati ("G. Jazzolino" Hospital - Vibo Valentia - Italy)
Vanessa Gourbali (Evangelismos Hospital)
Giovanni Orlandi (University of Pisa)
Martina Giuntini (Azienda Ospedaliero-Universitaria Pisana)
Francesco Corea (Stroke Unit, Ospedale San Giovanni Battista)
Marta Bellesini (University of Insubria)
Theodore Karapanayiotides (Aristotle University of Thessaloniki)
Laszlo Csiba (Clinical Center, University of Debrecen)
Lilla Szabo (Department of Neurology, University of Debrecen, Debrecen, Hungary)
Davide Imberti (Internal Medicine)
Alessio Pieroni (Stroke Unit and Neurosonology Laboratory, Padua University Hospital)
Kristian Barlinn (Medical Faculty and University Hospital Carl Gustav Carus)
Lars-Peder Pallesen (University of Dresden)
Jessica Barlinn (Medical Faculty and University Hospital Carl Gustav Carus)
Boris Doronin (Novosibirsk State Medical University)
Vera Volodina (Neurology)

Giancarlo Agnelli (Department of Internal Medicine)

Dirk Deleu (The Neuroscience Institute (Stroke Center of Excellence))

Bruno Bonetti (Azienda Ospedaliera Universitaria Integrata)

Luana Gentile (IRCCS Istituto delle Scienze Neurologiche di Bologna)

Giuseppe Reale (Catholic University of the Sacred Heart)

Pietro Caliandro (Università Cattolica del Sacro Cuore, Policlinico Gemelli)

Andrea Morotti (ASST Spedali Civili)

Vieri Vannucchi (Santa Maria Nuova Hospital)

Marina Padroni (University of Ferrara)

Federica Letteri (Emergency Department, Stroke Unit, Sapienza University Hospital, Rome, Italy; Stroke

Unit, Neurology Department, Ospedale San Jacopo di Pistoia, Italy)

Mauro Magoni (Spedali Civili of Brescia)

Cindy Tiseo (University of L'Aquila)

Alberto Rigatelli (UOC Pronto Soccorso BT, AOUI Verona)

Aurelia Zauli (Catholic University of the Sacred Heart)

Francesco Bossi (Santa Maria della Misericordia Hospital, University of Perugia)

Valeria Caso (University of Perugia)

medRxiv preprint doi: <https://doi.org/10.1101/2024.04.19.24306111>; this version posted April 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](#).

All authors have read and approved the submitted manuscript, the manuscript has not been

submitted elsewhere nor published elsewhere in whole or in part.

Statin Therapy in Ischemic Stroke Patients with Atrial Fibrillation: Efficacy and Safety Outcomes

RAF and RAF NOAC-Investigators

Authors: Michele Marvardi¹, MD; Mario Ferrante², MD; Maurizio Paciaroni¹, MD, Azmil Abdul-Rahim^{3,4}, MD, Georgios Tsvigoulis⁵, MD; David Julian Seiffge⁷, MD; Stefan T. Engelter⁶, MD; Philippe Lyrer⁶, MD; Alexandros A. Polymeris⁶, MD; Tolga Dittrich^{6,88}, MD; Virginia Cancelloni¹, MD; Annaelle Zietz⁶, MMed, MD; Gian Marco De Marchis^{6,88}, MD, MSc; Jukka Putaala⁸, MD; Daniel Strbian⁸, MD, PhD; Liisa Tomppo⁸, MD, PhD; Patrik Michel⁹, MD; Davide Strambo⁹, MD; Alexander Salerno⁹, MD; Peter Vanacker^{10,11,12}, PhD; Susanna Zuurbier^{10,11}, MD; Laetitia Yperzeele^{10,11}, PhD; Caroline M.J. Loos^{10,11}, PhD; Manuel Cappellari¹³, MD; Andrea Emiliani¹³, MD; Marialuisa Zedde¹⁴, MD; MD; Cecilia Becattini¹, MD, PhD; Rosario Pascarella¹⁴, MD; Jesse Dawson¹⁵, MD; Robert Cronshaw¹⁵, MB BChir; Erika Schirinzi¹⁶, MD; Massimo Del Sette¹⁶, MD; Christoph Stretz¹⁷, MD; Narendra Kala¹⁷, MD; Ashley Schomer¹⁷, MD; Brian Mac Grory¹⁸, MB, BCh, BAO; Mahesh Jayaraman¹⁷, MD; Shadi Yaghi¹⁷, MD; Karen L. Furie¹⁷, MD, MPH; Luca Masotti¹⁹, MD; Elisa Grifoni¹⁹, MD; Danilo Toni²⁰, MD; Angela Risitano²⁰, MD; Anne Falcou²¹, MD; Luca Petraglia²⁰, MD; Enrico Maria Lotti²², MD; Lucia Pavolucci²², MD; Piergiorgio Lochner²³, MD; Giorgio Silvestrelli²⁴, PhD; Alfonso Ciccone²⁴, MD; Andrea Alberti¹, MD; Michele Venti¹, PhD; Ilaria Leone De Magistris¹, MD; Maria Giulia Mosconi¹, MD, Michela Giustozzi¹, MD; MD; Odysseas Kargiotis²⁵, MD; Alessandro Rocco²⁶, MD; Marina Diomedi²⁶, MD; Simona Marcheselli²⁷, MD; Kateryna Antonenko^{7,28}, MD; Eugenia Rota²⁹, MD; Tiziana Tassinari³⁰, MD; Valentina Saia³⁰, PhD; Francesco Palmerini³¹, MD; Paolo Aridon³², PhD; Valentina Arnao³³, PhD; Serena Monaco³³, MD; Salvatore Cottone³³, MD; Antonio Baldi³⁴, MD; Cataldo D'Amore³⁴, MD; Walter Ageno³⁵, MD; Samuela Pegoraro³⁵, MD; George Ntaios³⁶, MD; Anastasia Adamou³⁶, MD; Dimitrios Sagris³⁶, MD; Sotirios Giannopoulos³⁷, MD; Maria Kosmidou³⁷, MD; Evangelos Ntais³⁷, MD; Michele Romoli³⁸, MD; Leonardo Pantoni³⁹, PhD; Silvia Rosa⁴⁰, MD; Pierluigi Bertora³⁹, MD; Alberto Chiti⁴¹, MD; Isabella Canavero^{42,43}, MD; Carlo Emanuele Saggese⁴⁴, MD; Maurizio Plocco⁴⁴, MD; Elisa Giorli⁴⁵, MD; Lina Palaodimou⁵, MD; Eleni Bakola⁵, MD; Fabio Bandini⁴⁶, MD; Antonio Gasparro⁴⁷, MD; Valeria Terruso⁴⁷, MD; Marina Mannino⁴⁷, MD; Alessandro Pezzini^{48,49}, MD; Raffaele Ornello⁵⁰, MD; Simona Sacco⁵⁰, MD; Nemanja Popovic⁵¹, MD; Umberto Scoditti⁵², MD; Antonio Genovese⁵², MD; MD; Yuriy Flomin⁵, MD; Michelangelo Mancuso⁵⁴, MD; Roberto D'Agliano⁵⁴, MD; Marco Baldini⁵⁴, MD; Leonardo Ulivi⁵⁴, MD; Nicola Giannini⁵⁴, MD; Kostantinos Vadikolias⁵⁵, MD; Chrysoula Liantinioti⁵⁶, MD; Maria Chondrogianni⁵⁶, MD; Panagiotis Halvatsiotis⁵⁶, MD; Efstathia Karagkiozi³⁶ MD; George Athanasakis³⁶, MD; Kostantinos Makaritsis³⁶, MD; Alessia Lanari⁵⁷, MD, PhD; Turgut Tatlisumak⁵⁸, MD; Monica Acciarresi⁵⁹, MD; Gianni Lorenzini⁶⁰, MD; Rossana Tassi⁶¹, MD; Francesca Guideri⁶¹, MD; Maurizio Acampa⁶, MD; Giuseppe Martini⁶¹, MD; Sung-Il Sohn⁶², MD, PhD; Nicola Mumoli⁶³, MD; Davide Carrara⁶³, MD; Miriam Maccarrone⁶⁴, MD; Franco Galati⁶⁵, MD; Vanessa Gourbali⁶⁶, MD, PhD; Giovanni Orlandi⁵⁴, MD; Martina Giuntini⁶⁷, MD; Francesco Corea⁵⁸, MD, PhD; Marta Bellesini³⁶, MD; Theodore Karapanayiotides⁶⁸, MD, PhD; Laszlo Csiba⁷⁰, MD; Lilla Szabó⁷⁰, MD; Davide Imberti⁷¹, MD; MD; Alessio Pieroni⁷², MD; Kristian Barlinn⁷³, MD; Lars-Peder Pallesen⁷³, MD; Jessica Barlinn⁷³, MD; Boris Doronin⁷⁴, MD; Vera Volodina⁷⁴, MD; Giancarlo Agnelli¹, MD; Dirk Deleu⁷⁵, MD, PhD, FRCP; Bruno Bonetti¹³, MD; Luana Gentile⁷⁶, MD; Giuseppe Reale⁷⁷, MD; Pietro Caliandro⁷⁸, MD; Andrea Morotti⁷⁹, MD; Vieri Vannucchi⁸⁰, MD; Marina Padroni⁸¹, MD; Federica Letteri⁸², MD; Mauro Magoni⁸³, MD, PhD; Cindy Tiseo⁸⁴, MD; Alberto Rigatelli⁸⁵, MD; Aurelia Zauli⁸⁷, MD; Francesco Bossi¹, MD; Valeria Caso¹, PhD.

Affiliations:

¹Stroke Unit and Division of Cardiovascular Medicine, University of Perugia, Italy

- ³⁹Department of Biomedical and Clinical Sciences, University of Milan, Italy
- ⁴⁰Neurology Unit, ASST Fatebenefratelli – Sacco, Milan, Italy
- ⁴¹Neurologia, Ospedale Apuano, Massa Carrara, Italy
- ⁴²Emergency Neurology, IRCCS Casimiro Mondino Foundation, Pavia, Italy
- ⁴³Cerebrovascular Unit, Fondazione IRCCS Istituto Neurologico “Carlo Besta”, Milano, Italy
- ⁴⁴Unità di Terapia Neurovascolare. Ospedale "Fabrizio Spaziani", Frosinone, Italy
- ⁴⁵Stroke Unit, Department of Neurology, Sant'Andrea Hospital, La Spezia, Italy
- ⁴⁶Department of Neurology, ASL 3 Genovese, Genova, Italy
- ⁴⁷Department of Neurology and Stroke Unit, AOOR Villa Sofia-V. Cervello, Palermo, Italy
- ⁴⁸Department of Medicine and Surgery, University of Parma, Italy
- ⁴⁹Stroke Care Program, Department of Emergency, Parma University Hospital, Italy
- ⁵⁰ Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.
- ⁵¹ Clinic of Neurology, Clinical Center of Vojvodina, University of Novi Sad, Serbia
- ⁵² Stroke Care Program, Department of Emergency, Parma University Hospital, Italy
- ⁵³ Stroke and Neurorehabilitation Unit MC 'Universal Clinic 'Oberig' Kyiv, Ukraine
- ⁵⁴ Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, Italy
- ⁵⁵ Department of Neurology, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
- ⁵⁶ Second Department of Internal Medicine Research Unit and Diabetes Center, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Rimini 1 Chaidari, Athens, Greece
- ⁵⁷ Neurology & Stroke Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- ⁵⁸ Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden
- ⁵⁹ UO Gravi Cerebrolesioni, San Giovanni Battista Hospital, Foligno, Italy
- ⁶⁰ SC Medicina e Chirurgia d'Accettazione e d'Urgenza, Ospedale Lotti Pontedera, Azienda USL Toscana Nordovest
- ⁶¹ Stroke Unit, AOU Senese, Siena, Italy
- ⁶² Department of Neurology, Keimyung University School of Medicine, Daegu, South Korea
- ⁶³ Magenta Hospital, Magenta (MI), Italy
- ⁶⁴ Neurologia, Azienda Ospedaliera dell'Alto Adige, Italy
- ⁶⁵ Stroke Unit, Jazzolino Hospital, Vibo Valentia, Italy
- ⁶⁶ Department of Neurology, Evangelismos Hospital, Athens
- ⁶⁷ Neurologia, Ospedale Apuano, Massa Carrara, Italy
- ⁶⁸ 2nd Department of Neurology, Aristotle University of Thessaloniki, School of Medicine, AHEPA University Hospital, Thessaloniki, Greece
- ⁶⁹ Abteilung für Neurologie, Oberschwabenklinik gGmbH, Ravensburg, Germany
- ⁷⁰ Stroke Unit, University of Debrecen, Hungary
- ⁷¹ Department of Internal Medicine, Ospedale Civile di Piacenza, Italy
- ⁷² Stroke Unit, Azienda Ospedaliera Università di Padova, Padova, Italy
- ⁷³ Department of Neurology, Dresden University Stroke Center, Dresden, Germany
- ⁷⁴ Municipal Budgetary Healthcare Institution of Novosibirsk. City Clinical Hospital # 1. Novosibirsk at the Novosibirsk State Medical University, Russia
- ⁷⁵ Neurology, Hamad Medical Corporation, Doha, Qatar

medRxiv preprint doi: <https://doi.org/10.1101/2024.04.19.24306111>; this version posted April 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

⁷⁶ IRCCS Istituto delle Scienze Neurologiche di Bologna, Ospedale Maggiore Bologna, Italy

⁷⁷ UOC Neuroriabilitazione ad Alta Intensità, Dipartimento Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy

⁷⁸ UOC Neurologia, Dipartimento Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy

⁷⁹ Department of Clinical and Experimental Sciences, Neurology Unit, University of Brescia, Brescia, Italy

⁸⁰ SOS Medicina interna ad Alta intensità, Azienda USL Toscana Centro, Ospedale Santa Maria Nuova, Firenze

⁸¹ Neurology Unit, Sant'Anna University Hospital, Ferrara, Italy

⁸² SOC Neurologia, Ospedale San Jacopo, Pistoia, Italy

⁸³ Neurologia Vascolare - Stroke Unit ASST Spedali Civili Brescia

⁸⁴ Neurology and Stroke Unit, SS Filippo e Nicola Hospital, Avezzano, Italy

⁸⁵ Pronto Soccorso Borgo Trento, AOUI Verona, DAI Emergenze e accettazione

⁸⁶ Department of Neurology and Stroke Center, Kantonsspital St. Gallen, Switzerland

⁸⁷ Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy

Corresponding author: Michele Marvardi, MD

Stroke Unit and Division of Cardiovascular Medicine

University of Perugia, Italy 06121, Perugia, Italy

Phone: +39 333 7549696

Email: m.marvardi@outlook.it

ORCID: 0009-0007-3166-0836

Abstract

Background: The efficacy and safety of statins for secondary prevention in patients who have experienced a cardioembolic stroke are not well-defined. However, previous observational data reported hyperlipidemia as a risk factor for both ischemic and bleeding complications in patients with AF and previous stroke. Based on these premises, we conducted a sub-analysis of the RAF and RAF-NOAC studies to evaluate the efficacy and safety of statins in secondary prevention in patients with acute ischemic stroke and AF.

Methods: We combined patient data from the RAF and RAF-NOAC studies, prospective observational studies conducted across Stroke Units in Europe, the United States, and Asia from January 2012 to June 2016. We included consecutive patients with AF who suffered an acute ischemic stroke with a follow-up of 90 days. Our outcomes were the combined endpoint, including stroke, transient ischemic attack, systemic embolism, symptomatic intracerebral hemorrhage, and major extracranial bleeding. Furthermore, both ischemic and hemorrhagic outcomes were evaluated separately.

Results: A total of 1.742 patients were included (46% male), and 898 (52%) received statins after the index event. At multivariable analysis, statin use was statistically associated with age (OR 0.92, 95% CI 0.97 - 0.99, $p = 0.001$), male sex (OR 1.35, 95% CI 1.07 - 1.70, $p = 0.013$), anticoagulation (OR 2.53, 95% CI 1.90 - 3.36, $p < 0.0001$), hyperlipidemia (OR 5.52, 95% CI 4.28 - 7.12, $p < 0.0001$), paroxysmal AF (OR 1.40, 95% CI 1.12 - 1.75, $p = 0.003$), leukoaraiosis (OR 1.39, 95% CI 1.11 - 1.75, $p = 0.004$) and heart failure (OR 0.72, 95% CI 0.53 - 0.98, $p = 0.034$). Statin use was not associated with the combined outcome event (OR 0.81, 95% CI 0.56 - 1.19, $p = 0.286$) and ischemic outcome event (OR 1.13, 95% CI 0.71 - 1.82, $p = 0.604$) while was associated with a lower risk of hemorrhagic outcome event (OR 0.49, 95% CI 0.27 - 0.88, $p = 0.016$).

Conclusions: Our data show that statins seem to protect against global bleeding events in cardioembolic stroke patients; this may be due to the pleiotropic effect of statins. More data are warranted to confirm these findings.

Background

While randomized controlled trials (RCTs) have evaluated statins for their potential in preventing recurrent acute ischemic stroke related to atherosclerosis, including large vessel occlusion (LVO) and small vessel disease (SVD), their effectiveness for ischemic stroke of cardioembolic origin remains unclear¹⁻⁴. Although there is a well-documented link between high LDL cholesterol and increased risk of acute ischemic stroke due to LVO and SVD, the association with cardioembolic stroke is not yet clear.^{3-7 8-10} The RENO and RENO-ICH studies identified hyperlipidemia as a statistically significant risk factor for both ischemic and hemorrhagic recurrences in patients with cardioembolic stroke.^{11,12} Additionally, the RENO study revealed that approximately one-third of recurrent events were caused by LVO and SVD rather than cardioembolism.¹¹ Notably, statins have demonstrated efficacy in reducing the risk of such non-cardioembolic events.^{11 13,14}

Beyond their role in lowering cholesterol, statins are known for their benefits in plaque stabilization, endothelial protection, and anti-inflammatory and anti-thrombotic effects—which may theoretically reduce the risk of acute ischemic stroke from any causes.^{15 16}

Despite the benefits, there is a described risk of increased bleeding events, particularly intracerebral, reported mainly in secondary prophylaxis. Two large RCTs including patients with non-cardioembolic stroke, the Heart Protection Study (HPS) and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study, showed a reduction in the number of cerebral ischemic events in the group of statin-treated patients but a statistically significant increase of bleeding events was observed, also in secondary prophylaxis.^{8,9}

Based on these premises, we conducted a sub-analysis of the RAF and RAF-NOAC studies to evaluate the efficacy and safety of statins in secondary prevention in patients with ischemic stroke and AF.

Methods

The data that supported the findings of this study are available from the corresponding author upon reasonable request.

We merged the datasets from the RAF and RAF-NOAC studies, both prospective observational studies.

^{17,18} The RAF study was conducted from January 2012 to March 2014 in 29 Stroke Units, while the RAF-NOAC study spanned from April 2014 to June 2016 in 35 Stroke Units throughout Europe, the United States, and Asia. ^{17,18} Both studies recruited patients who experienced an acute ischemic stroke and were diagnosed with AF, either prior to or following their stroke, with no contraindications to anticoagulant therapy. Ethical approval for both studies was obtained from local Institutional Review Boards as necessary.

The stroke severity was evaluated upon admission using the NIH Stroke Scale (NIHSS). All patients underwent either a non-contrast CT or an MR scan to rule out intracranial hemorrhage. Revascularization treatments, following the local standard protocols, were administered when indicated. Standard care in the Stroke Unit, along with monitoring and treatment, adhered to the international guidelines for acute ischemic stroke. Decisions regarding the selection and initiation timing of anticoagulants for secondary prevention were at the discretion of the attending physicians. The RAF study encompassed patients prescribed vitamin K antagonists or NOACs, whereas the RAF-NOAC study was exclusive to those treated with NOACs. Comprehensive medical history, clinical assessment, admission ECG, and 48-hour ECG monitoring post-index stroke were conducted to identify non-valvular AF, which was then classified accordingly:

- Paroxysmal: associated with episodes terminating spontaneously within seven days;
- Persistent: associated with episodes lasting more than seven days or requiring pharmacological and/ or electrical cardioversion;
- Permanent: persisting for more than one year, either because cardioversion had failed or had not been pursued.

Risk factors

We collected data on established stroke risk factors, including age, gender, and medical histories of hypertension, diabetes mellitus, smoking, hyperlipidemia, ischemic heart disease, peripheral arterial disease, alcohol abuse, obesity, and prior stroke or transient ischemic attack (TIA). Hypertension was defined by a blood pressure reading of $\geq 140/90$ mmHg on at least two occasions prior to the stroke or current antihypertensive medication use. Diabetes mellitus was identified by fasting glucose levels ≥ 126 mg/dL, postprandial levels ≥ 200 mg/dL, HbA1c $\geq 6.5\%$, or ongoing antidiabetic treatment. Hyperlipidemia at admission was defined by total cholesterol ≥ 200 mg/dL, triglycerides ≥ 140 mg/dL, or existing lipid-lowering therapy. Symptomatic ischemic heart and peripheral arterial diseases were confirmed through clinical history and diagnostic procedures.

Additionally, we evaluated white matter changes, categorizing leukoaraiosis (defined on the first computed tomography examination as ill-defined and moderately hypodense areas of ≥ 5 mm) on initial CT or MR imaging as absent or present, regardless of severity.¹⁹

Baseline measurements at admission for all patients included fasting serum glucose, cholesterol profiles (total, HDL, and LDL), platelet count, coagulation times, and blood pressure.

Physicians prescribed statins based on clinical judgment from among the seven commercially available in Europe, the United States, and Asia. We also documented the use of antiplatelet, anticoagulant, and thrombolytic agents before and during the study.

Outcomes

Primary study outcome at 90 days was defined as the composite of, ischemic stroke, transient ischemic attack, symptomatic systemic embolism, symptomatic intracerebral hemorrhage, and major extracranial hemorrhage. Additionally, ischemic and hemorrhagic events were analyzed separately.

Stroke was defined as the sudden onset of a new focal neurological deficit of a vascular origin in a site consistent with the territory of a major cerebral artery, and categorized as either ischemic or hemorrhagic. Hemorrhagic transformations revealed on neuroimaging 24-72h after onset were not considered outcome events, unless they were classified as being symptomatic. TIA was defined as a

transient episode of neurological dysfunction caused by focal brain ischemia without acute infarction.

Systemic embolism was defined as an acute vascular occlusion of an extremity or organ confirmed at imaging, surgery, or autopsy. Major extracerebral bleeding was defined as a reduction in the hemoglobin level of at least 2g per deciliter, requiring a blood transfusion of at least 2U, or symptomatic bleeding in a critical area or organ.

Statistical analyses

For patients with or without statins after the index event and with or without primary outcome event at 90 days, differences in clinical characteristics and risk factors were evaluated using the χ^2 test of proportions (with a 2-sided α level of 5%), by calculating odds ratio (OR) and 95% confidence intervals (CIs). Multivariable logistic regression analysis was performed to identify independent associations with statin use and outcome events. The variables included in this analysis were the following: age, sex, oral anticoagulant therapy, diabetes, hypertension, hyperlipidemia, paroxysmal atrial fibrillation, history of stroke/TIA, alcoholism, heart failure, history of myocardial infarction, peripheral arterial disease, leukoaraiosis, and smoking (CHA₂DS₂-VASc and total cholesterol were excluded due to the concurrent presence within the multivariate analysis of the individual factors already included in the CHA₂DS₂-VASc score and hyperlipidemia). Subsequent analyses were conducted to identify independent predictive factors for both the Ischemic Outcome and the Hemorrhagic Outcome events, including the same predictive factors used previously.

Finally, we carried out Cox Regression analyses (Cox proportional hazard model) to study in detail the effect of statins over the 90 days of follow-up on the Hemorrhagic Outcome and symptomatic intracranial hemorrhage; the variables included in these two analyses were the same: statin therapy, hyperlipidemia, paroxysmal atrial fibrillation, and CHA₂DS₂-VASc ≥ 4 . The results of the Cox Regression are reported in Hazard Ratios (HR).

Results

In total, the study enrolled 1,742 patients. After excluding 34 due to incomplete follow-up data, the analysis included 1,708 participants. Among them, 811 (46.6%) were male and with a mean age of 76+/-9.86.

In this cohort of 1,708 patients, 898 (52%) were prescribed statins after the index event. Atorvastatin was the most common, used by 28.5% of patients, followed by Simvastatin at 12.8% and Rosuvastatin

at 5.6%. A smaller number (0.6%) were on Pravastatin. Fluvastatin and Pitavastatin were the least used, with only one patient on each. Data on statin usage was missing for 69 (4%). Only 13 (0.7%) of patients received Ezetimibe, excluded in the statistical analyses.

Regarding anticoagulant therapy, 1,380 (79.2%) patients received treatment, 841 (48.3%) on NOACs, and 539 (30.9%) on Warfarin. The remaining 361 (20.7%) were not on oral anticoagulants, most commonly used subcutaneous low molecular weight heparin or, less frequently, antiplatelet drugs alone. In Table 1 are listed the main risk factors.

Predictors for statin therapy

The clinical characteristics of the patients treated and not treated with statins are listed in Table S1. Statin therapy was more frequent in younger patients (74.28 ± 9.07 vs 77.20 ± 10.49 , $p < 0.0001$), those taking oral anticoagulants (57% vs 39%, $p < 0.0001$), in patients with hyperlipidemia (50.0% vs 15.4%, $p < 0.0001$), in those with paroxysmal AF (46.8% vs 37.0%, $p < 0.0001$), and in those with a history of myocardial infarction (18.2% vs 10.9%, $p < 0.0001$). Statistical significance was also shown in diabetic patients (25.7% vs 19.5%, $p = 0.002$), hypertensive patients (80.2% vs 72.8%, $p = 0.003$), in those with a history of cerebral ischemic events (acute ischemic stroke/TIA, 28.6% vs 23.6%, $p = 0.022$), in those with leukoaraiosis on imaging studies (52.1% vs 46.6%, $p = 0.024$), and in smokers, current or past (32.7% vs 28.6%, $p = 0.037$).

The multivariable analysis identified oral anticoagulation (OR 2.53, 95% CI 1.90 - 3.36, $p < 0.0001$) and hyperlipidemia (OR 5.52, 95% CI 4.28 - 7.12, $p < 0.0001$) as predictors of statin therapy. Conversely, age had an inverse association with statin use (OR 0.98, 95% CI 0.97 - 0.99, $p = 0.001$), as did heart failure (OR 0.72, 95% CI 0.53 - 0.98, $p = 0.034$). In male patients, there was an increase in the likelihood of statin therapy (OR 1.35, 95% CI 1.07 - 1.70, $p = 0.013$). Statins were also more commonly prescribed among patients with paroxysmal atrial fibrillation (OR 1.40, 95% CI 1.12 - 1.75, $p = 0.003$) and leukoaraiosis (OR 1.39, 95% CI 1.11 - 1.75, $p = 0.004$).

Predictors for primary and secondary outcomes

A total of 134 patients (7.8%) experienced a primary outcome, whereas ischemic outcome was observed in 99 individuals (5.8%) and hemorrhagic outcomes in 70 individuals (4.1%). Symptomatic intracerebral hemorrhage alone was reported in 49 patients (2.9%).

A significant positive correlation among primary outcome and age was present: 78.0 ± 8.92 versus 75.71 ± 9.92 ($p = 0.005$). Also, diabetes was associated with primary outcome: 33.5% versus 21.6% ($p = 0.001$). Similarly, hypertension (86.0% vs 76.3%, $p = 0.006$) and PAD (15.2% vs 7.7%, $p = 0.003$) were statistically significant for primary outcome. Conversely, OAC was inversely associated with the primary outcome: 30.5% versus 49.2% ($p = 0.029$). Statin therapy also suggested a protective trend (44.5% vs 51.9%), but this did not reach statistical significance ($p = 0.084$) (Table S2).

On multivariable analysis, OAC was inversely correlated with primary outcome (OR 0.53, 95% CI 0.36 - 0.77, $p = 0.001$). Conversely, diabetes (OR 1.59, 95% CI 1.1 - 2.3, $p = 0.014$) and PAD (OR 1.97, 95% CI 1.18 - 3.29, $p = 0.009$) were associated with an increased risk of primary outcome. Statin use was associated with a reduced risk of primary outcome, but this association did not reach statistical significance (OR 0.81, 95% CI 0.53 - 1.19, $p = 0.286$).

Regarding secondary outcomes, the hemorrhagic event rate was lower in the statin group (2.9% compared to 5.4%, $p = 0.010$), as was the rate of symptomatic intracerebral hemorrhage (2.1% vs 3.7%, $p = 0.043$).

On multivariable analysis, statin use was associated with a 51% reduction of total bleeding events, within 90 days (OR 0.49, 95% CI 0.27 - 0.88, $p = 0.016$) and this effect remains stable over the 90 days as shown in the Cox survival curve analysis (Figure 1). Regarding the symptomatic intracerebral hemorrhage outcome, statin therapy showed an early protective effect with a stable trend over the 90 days of follow-up, albeit in the absence of adequate statistical significance ($p = 0.066$) (Figure 2).

Discussion

In this observational study, which included a cohort of patients with AF in secondary prevention for ischemic stroke, statin therapy showed a statistically significant protective effect against global bleeding events during the 90 days following the index cerebral ischemic event. This correlation is probably due to a protective effect of statins against intracerebral hemorrhage. Whereas, for the Combined Outcome, statin therapy showed a protective trend, albeit without adequate statistical significance.

Our findings diverge from those of the Heart Protection Study and the SPARCL Trial, which both observed a statistically significant increase in bleeding events, particularly intracerebral hemorrhage.⁸

⁹ A subsequent meta-analysis which included data from 24 RCTs, including HPS and the SPARCL Trial, supported a trend towards increased bleeding events in patients undergoing secondary prophylaxis, with RR of 1.73 (95% CI 1.19 – 2.50).⁶ This analysis suggested that reduced LDL cholesterol could contribute to the increased risk of bleeding. However, it is important to note that data from the HPS and SPARCL trials predominantly influenced this result.^{8,9} Specifically, in the HPS, the incidence of ICH was 32 cases (21 in the Simvastatin group versus 11 in the placebo group). Given the small sample size, this did not confer statistical significance (RR 1.91, 95% CI 0.92 – 3.95), suggesting that the association may be less robust than initially perceived.⁸ In a sub-analysis of the SPARCL trial, which pooled patients who had an ICH, it was observed that ICH risk was higher in those having a hemorrhagic stroke as the entry event (HR 5.65, 95% CI 2.82 - 11.30, $p < 0.001$) without statistical interactions between statin therapy.²⁰ Consequently, the patients identified as having the highest risk for developing intracranial bleeding were those with a history of a previous bleeding event.

Data from comprehensive national registries in Denmark,²¹⁻²³ South Korea²⁴ and China,²⁵ encompassing nearly 1.5 million patients, consistently reported the safety of statins in preventing cerebral hemorrhagic events, both as primary and secondary prophylaxis.^{21, 22, 23, 25} Furthermore, the findings suggest that both the duration and the dosage of statin therapy contribute to a protective effect against intracerebral hemorrhage. Patients with prolonged statin use and those on higher

dosages had a lower risk of ICH, challenging the previously hypothesized biological mechanism linking LDL reduction to an increased bleeding risk.²⁶ These results are in line with those of an extensive meta-analysis published in 2012 for a total of 31 RCTs with 182,803 patients.²⁷ A similar meta-analysis by Hackman et al., which included published and unpublished data from 23 randomized trials and 19 observational studies, reported that statins were not associated with an increased risk of ICH neither in randomized trials (RR 1.10, 95% CI 0.86-1.41) or cohort studies (RR 0.94, 95% CI 0.81-1.10), both in primary (48% of patients included in RCTs) and in secondary (52% of patients included in RCTs) stroke prevention.^{28 29}

A recent Japanese study examining a patient cohort similar to ours investigated the impact of statins on individuals with AF who were also on oral anticoagulants. The Authors observed that the group treated with statins, compared to those not on statins, had a higher presence of paroxysmal AF, hypertension, diabetes, and dyslipidemia.³⁰ Notably, the statin group demonstrated a reduced risk of major bleeding. Furthermore, this group also showed decreased risks in all-cause mortality, ischemic events, and various types of strokes.³⁰

It is plausible that statins protect cerebral arterial vessels (particularly small vessels) from subacute damage due to hypertension, diabetes, and other harmful agents (such as reactive oxygen species, proinflammatory cytokines, etc.) due to their systemic anti-inflammatory and endothelium-protective effects.¹⁵

1. The reduction of cellular infiltration and metalloproteinase synthesis and the increase in collagen synthesis guarantee greater stability of the atheromatous plaque preventing plaque ulceration or, if it were already present, prevents its rupture with consequent acute thrombosis and vessel occlusion.
2. Anti-inflammatory effects are mainly due to the reduction of the synthesis of pro-inflammatory cytokines, in particular the C-Reactive Protein, and the NF- κ B complex. The systemic anti-inflammatory effect consequently reduces the oxidation of LDL, which underlies atherogenesis.

3. Statins also have an important protective effect on the vascular endothelium: they stimulate the production and release of nitric oxide by endothelial cells, which stimulates vasodilation and protects against endothelial damage thanks to its antioxidant properties.
4. Finally, statins enhance fibrinolysis by stimulating the production and release of t-PA, inhibit platelet aggregation by blocking the release of thromboxane in the blood stream and inhibit the extrinsic pathway of coagulation by reducing the expression of the tissue factor; this effect is added to that of any other antithrombotic ongoing therapies, and prevents thrombosis on plaque with occlusion of the vessel lumen which is the basis of major cardiovascular events.

The cumulative effects of statins may serve as a preventive measure against the onset or progression of cerebral small vessel disease. By safeguarding the integrity of small cerebral vessels, statins potentially mitigate the risk of ischemic events caused by thrombotic occlusions and hemorrhagic events due to the rupture of compromised vessels. Building on the same biological hypothesis, it is plausible that administering statins during the acute phase of an ischemic stroke could lower the likelihood of hemorrhagic transformation.

We did not perform logistic regression for the symptomatic intracranial hemorrhage outcome, due to the small sample size.

This study has several limitations:

- it is an observational study, based on data collected from databases of previous studies, in which neither the use nor the dosage of statins were randomized;
- the duration and intensity of the therapy, the type of statin and the LDL cholesterol levels at entry (index cerebral ischemic event) and at the time of the study outcome events were not considered;
- except for anticoagulants, additional medications that patients were taking besides statins were not included. As a result, we have no information on drug interactions that can potentially enhance or decrease the effects of statins;

- the 90-day follow-up is probably too limited to make conclusions, further studies are needed, both to confirm the safety of statin therapy in the acute and subacute phase, and subsequently to verify whether safety is maintained over a medium-long period of time.

However, this study has a large sample size which gives significant statistical value to the results of the analyses. It also has a prospective design and reflects the real-life experiences of many centers located on different continents (Europe, North America and Asia).

Conclusions

In this observational study, including patients with AF in secondary prevention for ischemic stroke, statin therapy showed a statistically significant protective effect against global bleeding events (intracranial and extracranial) during the 90 days following the index cerebral ischemic event. This correlation is mainly due to the protective effect of statins on an intracranial hemorrhage.

Table 1: Clinical characteristics of the patients enrolled in the study

	Patients (n:1742)
Age (y)	76 ± 9,86
Sex (male)	811 (46,6%)
Oral anticoagulants (OAC)	1380 (79,2%)
NOAC	841 (48,3%)
Warfarin	539 (30,9%)
No OAC	361 (20,7%)
Diabetes	396 (22,7%)
Hypertension	1343 (77,1%)

Hyperlipidemia	575 (33%)
AF classification	
paroxysmal	732 (42%)
persistent	307 (17,6%)
permanent	692 (39,7%)
History of stroke/TIA	456 (26,2%)
Alcoholism	121 (6,9%)
Heart failure	311 (17,8%)
History of myocardial infarction	255 (14,6%)
Peripheral arterial disease	149 (8,5%)
Leukoaraiosis	861 (49,4%)
CHA₂DS₂-VASc ≥ 4 Before or after???	1580 (90,6%)
Tobacco use (current or previous)	535 (30,7%)
Total cholesterol (mg/dL)	180,9 ± 44,3
Statins	898 (52%)
Atorvastatin	497 (28,5%)
Rosuvastatin	97 (5,6%)
Simvastatin	223 (12,8%)
Pravastatin	10 (0,6%)
Fluvastatin	1 (0,1%)
Pitavastatin	1 (0,1%)
Unspecified statin	69 (4%)

Table 2: Multivariate Analysis: Predictors for Statin Therapy

	OR	95% IC	P
Age (y)	0,98	0,97 – 0,99	0,001
Sex (male)	1,35	1,07 -1,70	0,013
Oral anticoagulants (OAC)	2,53	1,90 – 3,36	<0,0001
Diabetes	1,24	0,95 – 1,61	0,116
Hypertension	1,23	0,94 – 1,60	0,130
Hyperlipidemia	5,52	4,28 – 7,12	<0,0001
Paroxysmal AF	1,40	1,12 – 1,75	0,003
History of stroke/TIA	1,08	0,84 – 1,39	0,569

Alcoholism	1,44	0,93 – 2,25	0,106
Heart failure	0,72	0,53 – 0,98	0,034
History of myocardial infarction	1,27	0,91 – 1,78	0,158
Peripheral arterial disease	0,71	0,47 – 1,08	0,109
Leukoaraiosis	1,39	1,11 – 1,75	0,004
Tobacco use (current or previous)	0,87	0,67 – 1,12	0,281

Table 3: Multivariate Analysis: Predictors for Combined Outcome

	OR	95% IC	P
Age (y)	1,01	0,99 – 1,03	0,596
Sex (male)	0,96	0,66 – 1,41	0,842
Oral anticoagulants (OAC)	0,53	0,36 – 0,77	0,001
Diabetes	1,59	1,1 – 2,3	0,014
Hypertension	1,54	0,94 – 2,52	0,085
Hyperlipidemia	0,83	0,55 – 1,25	0,378
Paroxysmal AF	0,84	0,58 – 1,20	0,331
History of stroke/TIA	0,97	0,66 – 1,42	0,871

Alcoholism	1,53	0,81 – 2,91	0,190
Heart failure	1,17	0,77 – 1,79	0,463
History of myocardial infarction	1,16	0,73 – 1,84	0,543
PAD	1,97	1,18 – 3,29	0,009
Leukoaraiosis	1,25	0,87 – 1,77	0,224
Tobacco use (current or previous)	0,91	0,60 – 1,38	0,669
Statins	0,81	0,56 – 1,19	0,286

Table 4: Multivariate analysis on the role of statins on the combined, ischemic and hemorrhagic outcome

	OR (95% IC)	P
Combined Outcome	0,81 (0,56 – 1,19)	0,286
Ischemic Outcome	1,13 (0,71 – 1,82)	0,604
Hemorrhagic Outcome	0,49 (0,27 – 0,88)	0,016

Figure 1: Cox Regression: Statins as an Independent Predictive Factor for Hemorrhagic Outcome





Figure 2: Cox Regression: Statins as an Independent Predictor for Symptomatic Intracranial Hemorrhage.



References

1. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. *Stroke; a journal of cerebral circulation*. 2013;44:1833-1839. doi: 10.1161/STROKEAHA.113.001326
2. Koren-Morag N, Tanne D, Graff E, Goldbourt U. Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. *Arch Intern Med*. 2002;162:993-999. doi: 10.1001/archinte.162.9.993
3. Bezerra DC, Sharrett AR, Matsushita K, Gottesman RF, Shibata D, Mosley TH, Jr., Coresh J, Szklo M, Carvalho MS, Selvin E. Risk factors for lacune subtypes in the Atherosclerosis Risk in Communities (ARIC) Study. *Neurology*. 2012;78:102-108. doi: 10.1212/WNL.0b013e31823efc42
4. Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M, Tanizaki Y, Ibayashi S, Iida M, Kiyohara Y. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. *Stroke; a journal of cerebral circulation*. 2009;40:382-388. doi: 10.1161/STROKEAHA.108.529537
5. Simons LA, Simons J, Friedlander Y, McCallum J. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. *Atherosclerosis*. 2001;159:201-208. doi: 10.1016/s0021-9150(01)00495-6
6. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. *Lancet Neurol*. 2009;8:453-463. doi: 10.1016/S1474-4422(09)70058-4
7. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhalra N, Peto R, Barnes EH, Keech A, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376:1670-1681. doi: 10.1016/S0140-6736(10)61350-5
8. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet*. 2002;360:7-22. doi: 10.1016/S0140-6736(02)09327-3
9. Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillensen H, Simunovic L, Szarek M, Welch KM, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med*. 2006;355:549-559. doi: 10.1056/NEJMoa061894
10. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Bejot Y, Cabrejo L, Cha JK, Ducrocq G, Giroud M, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. *N Engl J Med*. 2020;382:9. doi: 10.1056/NEJMoa1910355
11. Paciaroni M, Agnelli G, Caso V, Silvestrelli G, Seiffge DJ, Engelter S, De Marchis GM, Polymeris A, Zedde ML, Yaghi S, et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. *Stroke; a journal of cerebral circulation*. 2019;50:2168-2174. doi: 10.1161/STROKEAHA.119.025350
12. Paciaroni M, Agnelli G, Giustozzi M, Caso V, Toso E, Angelini F, Canavero I, Micieli G, Antonenko K, Rocco A, et al. Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. *Stroke; a journal of cerebral circulation*. 2021;52:1450-1454. doi: 10.1161/STROKEAHA.120.031827
13. Tsvigoulis G, Katsanos AH, Sharma VK, Krogias C, Mikulik R, Vadikolias K, Mijajlovic M, Safouris A, Zompola C, Faissner S, et al. Statin pretreatment is associated with better outcomes in large artery atherosclerotic stroke. *Neurology*. 2016;86:1103-1111. doi: 10.1212/WNL.0000000000002493
14. Safouris A, Krogias C, Sharma VK, Katsanos AH, Faissner S, Roussopoulou A, Zompola C, Kneiphof J, Kargiotis O, Deftereos S, et al. Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2017;37:1415-1422. doi: 10.1161/ATVBAHA.117.309292

15. Pignatelli P, Carnevale R, Pastori D, Cangemi R, Napoleone L, Bartimoccia S, Nocella C, Basili S, Violi F. Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2. *Circulation*. 2012;126:92-103. doi: 10.1161/CIRCULATIONAHA.112.095554
16. Safouris A, Katsanos AH, Kerasnoudis A, Krogias C, Kinsella JA, Sztajzel R, Lambadiari V, Deftereos S, Kargiotis O, Sharma VK, et al. Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis. *Stroke; a journal of cerebral circulation*. 2018;49:1992-1995. doi: 10.1161/STROKEAHA.118.021542
17. Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, Rueckert C, Pezzini A, Poli L, Padovani A, et al. Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. *Stroke; a journal of cerebral circulation*. 2015;46:2175-2182. doi: 10.1161/STROKEAHA.115.008891
18. Paciaroni M, Agnelli G, Falocci N, Tsvigoulis G, Vadikolias K, Liantinioti C, Chondrogianni M, Bovi P, Carletti M, Cappellari M, et al. Early Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. *J Am Heart Assoc*. 2017;6. doi: 10.1161/JAHA.117.007034
19. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. *Stroke; a journal of cerebral circulation*. 2001;32:1318-1322. doi: 10.1161/01.str.32.6.1318
20. Goldstein LB, Amarenco P, Szarek M, Callahan A, 3rd, Hennerici M, Sillesen H, Zivin JA, Welch KM, Investigators S. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. *Neurology*. 2008;70:2364-2370. doi: 10.1212/01.wnl.0000296277.63350.77
21. Ribe AR, Vestergaard CH, Vestergaard M, Fenger-Gron M, Pedersen HS, Lietzen LW, Brynningsen PK. Statins and Risk of Intracerebral Haemorrhage in a Stroke-Free Population: A Nationwide Danish Propensity Score Matched Cohort Study. *EClinicalMedicine*. 2019;8:78-84. doi: 10.1016/j.eclinm.2019.02.007
22. Rudolph DA, Hald SM, Garcia Rodriguez LA, Moller S, Hallas J, Goldstein LB, Gaist D. Association of Long-term Statin Use With the Risk of Intracerebral Hemorrhage: A Danish Nationwide Case-Control Study. *Neurology*. 2022;99:e711-e719. doi: 10.1212/WNL.0000000000200713
23. Jung M, Lee S. Effects of Statin Therapy on the Risk of Intracerebral Hemorrhage in Korean Patients with Hyperlipidemia. *Pharmacotherapy*. 2019;39:129-139. doi: 10.1002/phar.2211
24. Park JH, Chung JW, Bang OY, Kim GM, Choi KH, Park MS, Kim JT, Hwang YH, Song TJ, Kim YJ, et al. Atherosclerotic Burden and Vascular Risk in Stroke Patients With Atrial Fibrillation. *Stroke; a journal of cerebral circulation*. 2021;52:1662-1672. doi: 10.1161/STROKEAHA.120.032232
25. Huang JY, Chan YH, Tse YK, Yu SY, Li HL, Chen C, Zhao CT, Liu MY, Wu MZ, Ren QW, et al. Statin Therapy Is Associated With a Lower Risk of Heart Failure in Patients With Atrial Fibrillation: A Population-Based Study. *J Am Heart Assoc*. 2023;12:e032378. doi: 10.1161/JAHA.123.032378
26. Yaghi S, Henninger N, Giles JA, Leon Guerrero C, Mistry E, Liberman AL, Asad D, Liu A, Nagy M, Kaushal A, et al. Ischaemic stroke on anticoagulation therapy and early recurrence in acute cardioembolic stroke: the IAC study. *J Neurol Neurosurg Psychiatry*. 2021;92:1062-1067. doi: 10.1136/jnnp-2021-326166
27. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. *Stroke; a journal of cerebral circulation*. 2012;43:2149-2156. doi: 10.1161/STROKEAHA.112.655894
28. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. *Circulation*. 2011;124:2233-2242. doi: 10.1161/CIRCULATIONAHA.111.055269

29. Katsanos AH, Lioutas VA, Charidimou A, Catanese L, Ng KKH, Perera K, de Sa Boasquevisque D, Falcone GJ, Sheth KN, Romero JR, et al. Statin treatment and cerebral microbleeds: A systematic review and meta-analysis. *J Neurol Sci.* 2021;420:117224. doi: 10.1016/j.jns.2020.117224
30. Uchida K, Ueda S, Sakakibara F, Kinjo N, Nezu M, Arai H, Morimoto T. Statins Reduce Bleeding Risk in Patients Taking Oral Anticoagulants for Nonvalvular Atrial Fibrillation: A Retrospective Registry Study. *Am J Cardiovasc Drugs.* 2023;23:89-99. doi: 10.1007/s40256-022-00555-4

Table S1: Univariate analysis: predictors for statin therapy

	Statins (n: 898)	No Statins (n. 844)	P
Age (y)	74,78 ± 9,07	77,20 ± 10,49	<0,0001
Sex (male)	454 (50,5%)	357 (42,3%)	0,001
Oral anticoagulants (OAC)			<0,0001
NOAC	512 (57%)	329 (39%)	
Warfarin	265 (29,5%)	274 (32,5%)	
No OAC	120 (13,4%)	241 (29%)	
Diabetes	231 (25,7%)	165 (19,5%)	0,002
Hypertension	720 (80,2%)	623 (73,8%)	0,003
Hyperlipidemia	445 (50%)	130 (15,4%)	<0,0001
Paroxysmal AF	420 (46,8%)	312 (37%)	<0,0001
History of stroke/TIA	257 (28,6%)	199 (23,6%)	0,022
Alcoholism	70 (7,8%)	51 (6%)	0,157
Heart failure	150 (16,7%)	161 (19,1%)	0,211
History of myocardial infarction	163 (18,2%)	92 (10,9%)	<0,0001
Peripheral arterial disease	88 (9,8%)	61 (7,2%)	0,06
Leukoaraiosis	468 (52,1%)	393 (46,6%)	0,024
CHA ₂ DS ₂ -VASc ≥ 4	816 (90,9%)	764 (90,5%)	0,714
Tobacco use (current or previous)	294 (32,7%)	241 (28,6%)	0,037
Total cholesterol (mg/dL)	179,57 ± 46,74	182,23 ± 41,55	0,237

Table S2: Univariate analysis: predictors for Combined Outcome

	Combined Outcome (n: 164)	No Combined Outcome (n. 1544)	P (sign <0,05)
Age (y)	78,00 ± 8,92	75,71 ± 9,92	0,005
Sex (male)	72 (43,9%)	720 (46,6%)	0,511
Oral anticoagulants (OAC)			0,029
NOAC	50 (30,5%)	759 (49,2%)	
Warfarin	56 (34,1%)	483 (31,3%)	
No OAC	58 (35,4%)	303 (19,6%)	
Diabetes	55 (33,5%)	333 (21,6%)	0,001
Hypertension	141 (86%)	1178 (76,3%)	0,006
Hyperlipidemia	54 (32,9%)	512 (33,2%)	1,000
Paroxysmal AF	58 (35,4%)	662 (42,9%)	0,067
History of stroke/TIA	44 (26,8%)	403 (26,1%)	0,852
Alcoholism	14 (8,5%)	105 (6,8%)	0,416
Heart failure	38 (23,2%)	268 (17,4%)	0,069
History of myocardial infarction	30 (18,3%)	218 (14,1%)	0,162
Peripheral arterial disease	25 (15,2%)	119 (7,7%)	0,003
Leukoaraiosis	92 (56,1%)	741 (48%)	0,058
CHA₂DS₂-VASc ≥ 4	159 (97%)	1389 (90%)	0,002
Tobacco use (current or previous)	48 (29,3%)	479 (31%)	0,721
Statin therapy	73 (44,5%)	801 (51,9%)	0,084

Table S3: Univariate Analysis on Statins and Combined and Secondary Outcomes

	Statin Therapy (n: 874)	No Statin Therapy (n. 835)	P
Combined Outcome	73 (8,4%)	91 (10,9%)	0,084
Ischemic Outcome	49 (5,6%)	50 (6%)	0,757
Hemorrhagic Outcome	25 (2,9%)	45 (5,4%)	0,010